Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi

doi:10.1002/ijc.30063

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22.

Authors

Julia M L Brotherton^{1

2}, Mark Jit^{3

4}, Patti E Gravitt⁵, Marc Brisson⁶, Aimée R Kreimer⁷, Sara I Pai⁸, Carole Fakhry⁹, Joseph Monsonego¹⁰, Silvia Franceschi¹¹

Affiliations

¹ National HPV Vaccination Program Register, VCS Registries, East Melbourne, Vic, Australia.
² School of Population and Global Health, University of Melbourne, Vic, Australia.
³ Modelling and Economics Unit, Public Health England, London, United Kingdom.
⁴ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
⁵ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM.
⁶ Département de Médecine Sociale et Préventive, Université Laval, Québec, QC, Canada.
⁷ Infections & Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD.
⁸ Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
⁹ Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Outpatient Center, Baltimore, MD.
¹⁰ Institut du Col, 174 Rue de Courcelles, Paris, 75017, France.
¹¹ International Agency for Research on Cancer, 69372 Lyon cedex 08, France.

Abstract

This review is one of two complementary reviews that have been prepared in the framework of the Eurogin Roadmap 2015 to evaluate how knowledge about HPV is changing practices in HPV infection and disease control through vaccination and screening. In this review of HPV vaccine knowledge, we present the most significant findings of the past year which have contributed to our knowledge of the two HPV prophylactic vaccines currently in widespread use and about the recently licensed nonavalent HPV vaccine. Whereas anal cancer is dealt with in the companion mini-review on screening, we also review here the rapidly evolving evidence regarding HPV-associated head and neck cancer and priority research areas.

Keywords: HPV; cervical cancer; oropharyngeal cancer; vaccine.

Publication types

Review

MeSH terms

Europe / epidemiology
Female
Head and Neck Neoplasms / epidemiology
Head and Neck Neoplasms / etiology
Head and Neck Neoplasms / prevention & control
Humans
Incidence
Male
Mass Screening
Neoplasms / epidemiology
Neoplasms / etiology
Neoplasms / prevention & control
Outcome Assessment, Health Care
Papillomavirus Infections / prevention & control*
Papillomavirus Vaccines / administration & dosage
Papillomavirus Vaccines / adverse effects
Papillomavirus Vaccines / classification
Papillomavirus Vaccines / immunology*
Uterine Cervical Neoplasms / epidemiology
Uterine Cervical Neoplasms / etiology*
Uterine Cervical Neoplasms / pathology
Uterine Cervical Neoplasms / prevention & control*
Vaccination

Substances

Papillomavirus Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding